Dr. Zhu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Lake Ave N
Worcester, MA 01655Phone+1 508-334-3550
Education & Training
- Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
- Hackensack University Medical Center/Englewood Hospital and Medical CenterResidency, Internal Medicine, 2009 - 2011
- Shanghai Medical UniversityClass of 2000
Certifications & Licensure
- CA State Medical License 2014 - 2026
- MA State Medical License 2010 - 2026
- NY State Medical License 2016 - 2025
- NJ State Medical License 2009 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 255 citationsAcquired Resistance to KRASG12C Inhibition in CancerMark M. Awad, Shengwu Liu, Igor I. Rybkin, Kathryn C. Arbour, Julien Dilly
The New England Journal of Medicine. 2021-06-23 - 829 citationsImmune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJulien Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot
Annals of Oncology. 2019-08-01 - 55 citationsGoing beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.Shannon S. Zhang, Misako Nagasaka, Viola W. Zhu, Sai-Hong Ignatius Ou
Lung Cancer. 2021-06-12
Journal Articles
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
- Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK+ Non-Small Cell Lung Cancer: A Histological AnalysisViola Zhu, MD, Clinical Lung Cancer
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Press Mentions
- OncLive® Hosts the Latest State of the Science Summit™ on Non-Small Cell Lung CancerApril 29th, 2019
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: